
M Eugene Sherman
Articles
-
Mar 13, 2023 |
opmed.doximity.com | Robert Sidney Rosenson |Amgad Nihad Makaryus |Leila Haghighat |M Eugene Sherman
Skip to main contentVoices from the Doximity NetworkUse AppShow Me Respect! A Clinical Trial of Statin Intolerant PatientsOp-Med is a collection of original articles contributed by Doximity members. The CLEAR Outcomes trial is a phase 3 trial that randomized 13,970 participants with statin intolerance.
-
Mar 13, 2023 |
opmed.doximity.com | Amgad Nihad Makaryus |Leila Haghighat |M Eugene Sherman |Robert Sidney Rosenson
Op-Med is a collection of original articles contributed by Doximity members. It was once again great to attend the American College of Cardiology Scientific Sessions 2023 together with the World Congress of Cardiology in person in New Orleans. Similar to last year, and even greater this year, more and more colleagues felt confident and willing to attend in person as we have emerged from the COVID-19 pandemic.
-
Mar 13, 2023 |
opmed.doximity.com | George Vetrovec |Amgad Nihad Makaryus |Leila Haghighat |M Eugene Sherman
Op-Med is a collection of original articles contributed by Doximity members. Live meetings are back! In-person meetings have been in recovery mode over the last 18 months. Last year, the ACC 2022 meeting was remarkable in the tangible joy so many showed in seeing old friends and colleagues after the COVID-19 hiatus. This year, there were still reacquaintances occurring, but there were fewer of them.
-
Mar 13, 2023 |
opmed.doximity.com | M Eugene Sherman |Amgad Nihad Makaryus |Leila Haghighat |George Vetrovec
Op-Med is a collection of original articles contributed by Doximity members. ACC 2023/WCC was a well-attended international meeting in New Orleans, March 4-6, 2023.
-
Mar 13, 2023 |
opmed.doximity.com | Leila Haghighat |Amgad Nihad Makaryus |M Eugene Sherman |George Vetrovec
Op-Med is a collection of original articles contributed by Doximity members.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →